SCYNEXIS, Inc. (NASDAQ: SCYX)

Join This Class Action

NEW YORK, NY – March 17, 2017 – Wolf Haldenstein Adler Freeman & Herz LLP   announces that  a class action lawsuit has been filed against SCYNEXIS, Inc. (“Scynexis” or  the“Company”) (NASDAQ: SCYX)  in the United States  District Court for the District of  New Jersey. The filed complaint is on behalf  of  a  class consisting  of  investors  who purchased or  otherwise  acquired  Scynexis securities:  (1)  pursuant  and/or traceable  to  Scynexis’  false  and  misleading  Registration  Statement  and Prospectus, issued in connection with the Company’s initial public offering on or about May 2,  2014 (the “IPO”  or the “Offering”); and/or  (2) on the  open market between May 2, 2014 and March 2, 2017, both dates inclusive (the “Class Period).

Investors who have incurred losses in the shares of SCYNEXIS, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.  

If   you have purchased shares of SCYNEXIS, Inc. and would like to assist with the litigation process, you may, no later than May 8, 2017, request that the Court appoint you lead plaintiff of the proposed class.

Scynexis, Inc.  is a pharmaceutical  company  that develops  and  distributes intravenous drugs for the treatment  of serious and life-threatening  invasive fungal infections in humans.

The Complaint  alleges  that  throughout the  Class  Period,  Defendants  made materially false and/or misleading statements,  as well as failed to  disclose  material  adverse  facts  about   the  Company’s  business,  operations,   and  prospects.  Specifically, Defendants made  false and/or misleading  statements and/or failed to disclose that:  (i) Scynexis’s lead product SCY-078  entailed substantial undisclosed  health  and  safety  risks;  (ii)  consequently,  the Company had  overstated  the  drug’s  approval  prospectus  and/or  commercial viability;  and  (iii)  as  a  result  of  the  foregoing,  Scynexis’s  public statements were materially false and misleading at all relevant times.

On March 2, 2017,  after the close of trading, Scynexis issued a  press release, entitled “Scynexis delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request,” announcing  the FDA’s clinical hold on clinical trials for the intravenous formulation of  the Company’s lead product  candidate SCY-078.    The Company  stated that  “[t]he clinical hold  decision was  issued by  the FDA  following a  review of  three mild-to-moderate thrombotic  events in  healthy  volunteers receiving  the  IV formulation of SCY-078 at  the highest doses and  highest concentrations in  a Phase 1 study.”  On this news, Scynexis’s share price fell $0.57, or  17.43%, to close at $2.70 on March 3, 2017.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at classmember@whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Certification and Authorization Pursuant to Federal Securities Laws
  • The individual or entity listed below authorizes and, upon execution of the accompanying retainer agreement by Wolf Haldenstein Adler Freeman & Herz LLP, retains Wolf Haldenstein Adler Freeman & Herz LLP to file an action under the federal securities laws to recover damages and to seek other relief against SCYNEXIS, Inc. (NASDAQ: SCYX). Wolf Haldenstein Adler Freeman & Herz LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses. The SCYNEXIS, Inc. (NASDAQ: SCYX) Retention Agreement provided to the Plaintiff is incorporated by reference, upon execution by Wolf Haldenstein Adler Freeman & Herz LLP.

  • I, individually or on behalf of the entity I represent ("I"), hereby certify as follows:

    1. I have reviewed the complaint and authorize the filing of a lead plaintiff motion or action on my behalf.
    2. I did not acquire the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this private action or any other litigation under the federal securities laws.
    3. I am willing to serve as a representative party on behalf of a class, including providing testimony at deposition and trial, if necessary.
    4. I represent and warrant that I am fully authorized to enter into and execute this certification.
    5. I will not accept any payment for serving as a representative party on behalf of the class beyond my pro rata share of any recovery, except such reasonable costs and expenses (including lost wages) directly relating to the representation of the class as ordered or approved by the court.
    6. I have made no transaction(s) during the Class Period in the debt or equity securities that are the subject of this action except those set forth below:
  • Type of SecurityBuy Date (mm/dd/yy)# of SharesPrice per Share 
    Add a row
  • Type of SecuritySell Date (mm/dd/yy)# of SharesPrice per Share 
    Add a row
  • Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 03/29/2017